Silje Watterdal Syversen
Overview
Explore the profile of Silje Watterdal Syversen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
293
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Orbo H, de Matos Kasahara T, Wolf A, Bjorlykke K, Sexton J, Jyssum I, et al.
Lancet Reg Health Eur
. 2024 Dec;
48:101121.
PMID: 39624496
Background: As most people now have established hybrid immunity, the need for regular, updated SARS-CoV-2 vaccine boosters in patients with immune-mediated inflammatory diseases (IMIDs) is unclear. The study aim was...
2.
Gehin J, Klaasen R, Kristianslund E, Jyssum I, Sexton J, Warren D, et al.
RMD Open
. 2024 Nov;
10(4).
PMID: 39537558
Objectives: The objectives of this study are to identify a therapeutic serum level for adalimumab associated with remission and low disease activity in patients with rheumatoid arthritis. Methods: Associations between...
3.
Wolf A, Bjorlykke K, Orbo H, Bhandari S, Solum G, Kjonstad I, et al.
EBioMedicine
. 2024 Sep;
108:105317.
PMID: 39260039
Background: Understanding cellular responses to SARS-CoV-2 immunisations is important for informing vaccine recommendations in patients with inflammatory bowel disease (IBD) and other vulnerable patients on immunosuppressive therapies. This study investigated...
4.
Orbo H, Bjorlykke K, Sexton J, Jyssum I, Tveter A, Christensen I, et al.
RMD Open
. 2024 Apr;
10(2).
PMID: 38599653
Objectives: To assess incidence, severity and predictors of COVID-19, including protective post-vaccination levels of antibodies to the receptor-binding domain of SARS-CoV-2 spike protein (anti-RBD), informing further vaccine strategies for patients...
5.
Kared H, Jyssum I, Alirezaylavasani A, Egner I, Tran T, Tietze L, et al.
Front Immunol
. 2024 Mar;
15:1296273.
PMID: 38455062
Background: SARS-CoV-2 vaccination in rheumatoid arthritis (RA) patients treated with B cell-depleting drugs induced limited seroconversion but robust cellular response. We aimed to document specific T and B cell immunity...
6.
Brun M, Gehin J, Bjorlykke K, Warren D, Klaasen R, Sexton J, et al.
Lancet Rheumatol
. 2024 Feb;
6(4):e226-e236.
PMID: 38402891
Background: Antidrug antibodies to TNF inhibitors might affect clinical outcomes. Proactive therapeutic drug monitoring allows for early detection of antidrug antibodies and might reduce negative clinical consequences. We aimed to...
7.
Jyssum I, Gehin J, Sexton J, Kristianslund E, Hu Y, Warren D, et al.
Rheumatology (Oxford)
. 2023 Sep;
63(6):1746-1755.
PMID: 37773994
Objectives: To explore associations between serum adalimumab level, treatment response and drug survival in order to identify optimal drug levels for therapeutic drug monitoring of adalimumab. Also, to assess the...
8.
Wolf A, Ravussin A, Konig M, Overas M, Solum G, Kjonstad I, et al.
JCI Insight
. 2023 May;
8(12).
PMID: 37159281
Immune responses in people with multiple sclerosis (pwMS) receiving disease-modifying therapies (DMTs) have been of significant interest throughout the COVID-19 pandemic. Lymphocyte-targeting immunotherapies, including anti-CD20 treatments and sphingosine-1-phosphate receptor (S1PR)...
9.
Brun M, Bjorlykke K, Viken M, Stenvik G, Klaasen R, Gehin J, et al.
J Intern Med
. 2023 Feb;
293(5):648-655.
PMID: 36843323
Background: Immunogenicity to tumour necrosis factor inhibitors is a significant clinical problem leading to treatment failure and adverse events. The study aimed to assess human leukocyte antigen (HLA) associations with...
10.
Jorgensen K, Hoivik M, Chopra A, Saltyte Benth J, Ricanek P, Moum P, et al.
Scand J Gastroenterol
. 2023 Feb;
58(8):874-882.
PMID: 36788656
Objectives: Immune responses following SARS-CoV-2 vaccination in patients with inflammatory bowel disease (IBD) are not well characterized. The aims of this study were to explore the serological response associated with...